HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period

You may also be interested in...

Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011

Perrigo further delays plans for a generic version of Reckitt Benckiser's Mucinex, saying the product it once touted as a 2010 highlight may not emerge even during the firm's fiscal 2011

Reckitt Would Add Durex, Scholl Brands With SSL Acquisition

Reckitt Benckiser moves again to grow its consumer products business, particularly in Asian markets, with an offer to acquire Durex condoms and Scholl foot care products manufacturer SSL International

Perrigo Gains Pole Position In Private-Label Allegra Race

Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts